Heike Keilhack

6.9k total citations · 2 hit papers
47 papers, 3.2k citations indexed

About

Heike Keilhack is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Heike Keilhack has authored 47 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 11 papers in Oncology and 8 papers in Immunology. Recurrent topics in Heike Keilhack's work include Cancer-related gene regulation (19 papers), Epigenetics and DNA Methylation (15 papers) and Chromatin Remodeling and Cancer (12 papers). Heike Keilhack is often cited by papers focused on Cancer-related gene regulation (19 papers), Epigenetics and DNA Methylation (15 papers) and Chromatin Remodeling and Cancer (12 papers). Heike Keilhack collaborates with scholars based in United States, Germany and Japan. Heike Keilhack's co-authors include Robert A. Copeland, Sarah K. Knutson, Tim J. Wigle, Frank‐D. Böhmer, Kevin W. Kuntz, Mikel P. Moyer, Richard Chesworth, Benjamin G. Neel, Victoria M. Richon and Margaret Porter Scott and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Heike Keilhack

46 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

2013 581 citations Sarah K. Knutson, Natalie M. Warholic et al. profile →
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Heike Keilhack

Since Specialization

Citations

This map shows the geographic impact of Heike Keilhack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heike Keilhack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heike Keilhack more than expected).

Fields of papers citing papers by Heike Keilhack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heike Keilhack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heike Keilhack. The network helps show where Heike Keilhack may publish in the future.

Co-authorship network of co-authors of Heike Keilhack

This figure shows the co-authorship network connecting the top 25 collaborators of Heike Keilhack. A scholar is included among the top collaborators of Heike Keilhack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heike Keilhack. Heike Keilhack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selective Pharmaceutical Inhibition of PARP14 Mitigates Allergen-Induced IgE and Mucus Overproduction in a Mouse Model of Pulmonary Allergic Response 2022 ·ImmunoHorizons ·(unknown), Kevin W. Chen, Laurie B. Schenkel, Kerren K. Swinger, Jennifer R. Molina, Kaiko Kunii, Ariel Raybuck, Heike Keilhack, Katherine N. Gibson‐Corley, Mario Niepel, R. Stokes Peebles, Mark Boothby, Sung Hoon Cho	8
2	In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement 2020 ·Cell chemical biology ·Tim J. Wigle, (unknown), Laurie B. Schenkel, Yue Ren, (unknown), (unknown), Kerren K. Swinger, (unknown), Christina R. Majer, Alvin Lu, Mario Niepel, Nicholas R. Perl, Melissa M. Vasbinder, Heike Keilhack, Kevin W. Kuntz	17
3	Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation 2019 ·Biochemical Pharmacology ·Alvin Lu, Ryan Abo, Yue Ren, Bin Gui, Jan-Rung Mo, (unknown), Tim J. Wigle, Heike Keilhack, Mario Niepel	39
4	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study breakdown → 2018 ·The Lancet Oncology ·Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde, Jean‐Marie Michot, Carlo Lucchesi, Andréa Varga, Jean‐Michel Coindre, Stephen J. Blakemore, Alicia Clawson, Benjamin Suttle, Alice McDonald, Mark Woodruff, Scott Ribich, Eric Hedrick, Heike Keilhack, Blythe Thomson, Takashi Owa, Robert A. Copeland, Peter Ho, Vincent Ribrag	451
5	EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL 2017 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Allison E. Drew, Trupti Lingaraj, (unknown), Natalie M. Warholic, Igor Feldman, Christopher Plescia, J. Joshua Smith, Robert A. Copeland, Heike Keilhack, Elayne Chan-Penebre, Sarah K. Knutson, Scott Ribich, Alejandra Raimondi, Michael J. Thomenius	52
6	Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models 2017 ·Molecular Cancer Therapeutics ·Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew, Alexandra Grassian, Igor Feldman, Sarah K. Knutson, Kristy Kuplast‐Barr, Maria Roche, John Campbell, Peter Ho, Robert A. Copeland, Richard Chesworth, J. Joshua Smith, Heike Keilhack, Scott Ribich	127
7	In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells 2017 ·Methods in molecular biology ·Heike Keilhack, Paul Chang	2
8	Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma 2016 ·PLoS ONE ·Satoshi Kawano, Alexandra Grassian, Masumi Tsuda, Sarah K. Knutson, Natalie M. Warholic, Galina Kuznetsov, Shanqin Xu, Yonghong Xiao, Roy M. Pollock, (unknown), (unknown), Scott Ribich, Yukinori Minoshima, Junji Matsui, Robert A. Copeland, Shinya Tanaka, Heike Keilhack	58
9	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas 2014 ·PLoS ONE ·Sarah K. Knutson, Natalie M. Warholic, L. Danielle Johnston, Christine R. Klaus, Tim J. Wigle, (unknown), Bruce A. Littlefield, (unknown), J. Joshua Smith, Mikel P. Moyer, Robert A. Copeland, Roy M. Pollock, Kevin W. Kuntz, Alejandra Raimondi, Heike Keilhack	55
10	Preclinical Characterization of E7438, a Potent, Selective EZH2 Inhibitor with Robust Antitumor Activity Against EZH2 Mutated NHL Xenografts in Mice 2013 ·Annals of Oncology ·Heike Keilhack	3
11	A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients 2012 ·FEBS Letters ·Christina R. Majer, Lei Jin, Margaret Porter Scott, Sarah K. Knutson, Kevin W. Kuntz, Heike Keilhack, J. Joshua Smith, Mikel P. Moyer, Victoria M. Richon, Robert A. Copeland, Tim J. Wigle	116
12	Regulation of Brown Fat Adipogenesis by Protein Tyrosine Phosphatase 1B 2011 ·PLoS ONE ·Kosuke Matsuo, Ahmed Bettaieb, Naoto Nagata, Izumi Matsuo, Heike Keilhack, Fawaz G. Haj	35
13	Differential Regulation of Endoplasmic Reticulum Stress by Protein Tyrosine Phosphatase 1B and T Cell Protein Tyrosine Phosphatase 2011 ·Journal of Biological Chemistry ·Ahmed Bettaieb, Siming Liu, Yannan Xi, Naoto Nagata, Kosuke Matsuo, Izumi Matsuo, Samah Chahed, Jesse Bakke, Heike Keilhack, Tony Tiganis, Fawaz G. Haj	54
14	Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. 2011 ·Journal of Clinical Oncology ·Tami Yap, Libo Yan, (unknown), David Olmos, Ivy Fearen, Richard D. Baird, Kyriakos P. Papadopoulos, Nina Tunariu, Andrea Biondo, Heike Keilhack, (unknown), (unknown), (unknown), Celia L. Carpenter, Shaun Decordova, Simon P. Heaton, May Garrett, Dan M. Sullivan, Johann S. de Bono, A. W. Tolcher	9
15	Sensitive multiplexed analysis of kinase activities and activity-based kinase identification 2009 ·Nature Biotechnology ·Kazuishi Kubota, Rana Anjum, Yonghao Yu, Ryan C. Kunz, Jannik N. Andersen, Manfred Kraus, Heike Keilhack, Kumiko Nagashima, Stefan Krauß, Cloud P. Paweletz, Ronald C. Hendrickson, Adam S. Feldman, Chin‐Lee Wu, A. John Rush, Judit Villén, Steven P. Gygi	89
16	Comparative expression analysis of four breast cancer subtypes versus matched normal tissue from the same patients 2008 ·The Journal of Steroid Biochemistry and Molecular Biology ·Paolo Martini, Deanne Taylor, Jadwiga Biénkowska, Jennifer Jackson, Gregory McAllister, Heike Keilhack, R. Keith Campbell	3
17	Identification of Src Phosphorylation Sites in the Catenin p120 2001 ·Journal of Biological Chemistry ·(unknown), Panos Z. Anastasiadis, Heike Keilhack, Frank‐D. Böhmer, Jue Wang, Albert B. Reynolds	124
18	The Protein-tyrosine Phosphatase SHP-1 Binds to and Dephosphorylates p120 Catenin 2000 ·Journal of Biological Chemistry ·Heike Keilhack, Ulf Hellman, Jolanda van Hengel, Frans van Roy, Jasminka Godovac‐Zimmermann, Frank‐D. Böhmer	55
19	Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling 1998 ·Journal of Biological Chemistry ·Heike Keilhack, Tencho Tenev, (unknown), Jasminka Godovac‐Zimmermann, Lene Rostgaard Nielsen, Klaus Seedorf, Frank‐D. Böhmer	127
20	Both SH2 Domains Are Involved in Interaction of SHP-1 with the Epidermal Growth Factor Receptor but Cannot Confer Receptor-directed Activity to SHP-1/SHP-2 Chimera 1997 ·Journal of Biological Chemistry ·Tencho Tenev, Heike Keilhack, Siniša Tomić, (unknown), Matthias Stein-Gerlach, Reiner Lammers, Andrei V. Krivtsov, Axel Ullrich, Frank‐D. Böhmer	81

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact